# Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

> **NCT00005980** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 116 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00005980
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2002-07
- **Final completion:** —
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005980, "Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*